Risedronate Reduced Risk Of Fracture Among Osteoporotic Postmenopausal Women With History Of Hip Fracture

In a new analysis reported at the American Society for Bone and Mineral Research (ASBMR) 29th Annual Meeting, risedronate 5 mg decreased clinical fracture risk by 50% over three years relative to placebo in a group of postmenopausal women with osteoporosis who had suffered a previous hip fracture. This retrospective analysis of the risedronate HIP trial(1) evaluated the combined incidence of vertebral and nonvertebral clinical fractures among this high risk group of patients. [click link for full article]

More: continued here

Filed under: Bones on September 20th, 2007